MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
16.21
-0.14 (-0.86%)
Aug 18, 2026, 12:24 PM EDT - Market open

MLTX Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-268.34-244.83-143.09-54.12-65.06-34.29
Net Income
-263.67-227.32-118.94-36.01-49.97-64.37
Earnings Per Share
-3.81-3.53-1.89-0.73-1.70-8.21
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
537.03393.97448.03511.0172.118.04
Total Debt
101.5375.712.833.70.2815
Net Cash (Debt)
435.5318.26445.2507.3171.83-6.96
Net Cash Growth
24.67%-28.51%-12.24%606.24%--
Net Cash Per Share
6.304.947.0810.332.45-0.89

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-225.18-196.01-116.59-42.78-55.89-42.21
Capital Expenditures
--0.04-0.52-0.28-0.02-0.06
Free Cash Flow
-225.18-196.04-117.11-43.06-55.91-42.27
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.